Finch Therapeutics Group, Inc. (FNCHQ) Financial Statements
$10.20OTC: FNCHQMarket Cap $16.38M
Finch Therapeutics Group, Inc. most recently reported annual revenue of $0, a net loss of $14.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Finch Therapeutics Group, Inc.: Revenue fell from $10.0M in 2019 to $0 in 2024, a change of -100.0% over 5 years; net profit was positive in 0 of 6 reported years; operating margin moved from -208.2% to -31777.6%, a shift of -31569.4 percentage points; the most recent year shows a net loss of $14.0M.
Income Statement — 6 Years (USD millions)
Metric
2019
2020
2021
2022
2023
2024
Revenue
$10.0M
$8.0M
$19.0M
$1.0M
$0
$0
Operating Expenses
$31.0M
$47.0M
$79.0M
$96.0M
$34.0M
$19.0M
Operating Profit
$-21.0M
$-39.0M
$-60.0M
$-95.0M
$-34.0M
$-19.0M
Operating Margin
-208.2%
-510.9%
-323.7%
-11047.6%
-31777.6%
0.0%
Other Income
$0
$0
$2.0M
$-20.0M
$-44.0M
$5.0M
Interest
$0
$0
$0
$0
$0
$0
Depreciation
$0
$1.0M
$2.0M
$6.0M
$2.0M
$0
Profit Before Tax
$-21.0M
$-39.0M
$-58.0M
$-115.0M
$-78.0M
$-14.0M
Tax
$0
$0
$0
$0
$4.4M
$0
Net Profit
$-21.0M
$-39.0M
$-58.0M
$-115.0M
$-75.0M
$-14.0M
EPS
$-12.68
$-24.39
$-36.72
$-72.12
$-46.59
$-8.64
Dividend Payout
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Quarterly Results — Last 12 Quarters (USD millions)
6 duplicate period labels in the source data were collapsed.
Metric
Sep '21
Dec '21
Mar '22
Jun '22
Sep '22
Dec '22
Mar '23
Jun '23
Sep '23
Dec '23
Mar '24
Jun '24
Revenue
$11.0M
$1.0M
$0
$0
$0
$0
$0
$0
$0
$3.0M
$0
$0
Operating Expenses
$21.0M
$20.0M
$25.0M
$23.0M
$41.0M
$28.0M
$-30.0M
$10.0M
$4.0M
$8.0M
$5.0M
$6.0M
Operating Profit
$-10.0M
$-19.0M
$-25.0M
$-23.0M
$-41.0M
$-28.0M
$30.0M
$-10.0M
$-4.0M
$-5.0M
$-5.0M
$-6.0M
Operating Margin
-87.6%
-2365.0%
-6943.5%
-6268.4%
-29443.5%
-346900.0%
27861.7%
0.0%
0.0%
-164.5%
0.0%
0.0%
Interest
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Profit Before Tax
$-10.0M
$-19.0M
$-25.0M
$-23.0M
$-40.0M
$-27.0M
$-67.0M
$-7.0M
$-2.0M
$-3.0M
$-4.0M
$-5.0M
Tax
$0
$0
$0
$0
$0
$0
$5.1M
$0
$0
$0
$0
$0
Net Profit
$-10.0M
$-19.0M
$-25.0M
$-23.0M
$-40.0M
$-26.0M
$-64.0M
$-7.0M
$-2.0M
$-3.0M
$-4.0M
$-5.0M
EPS
$-6.29
$-12.04
$-15.50
$-14.36
$-25.21
$-16.48
$-39.89
$-4.33
$-1.51
$-1.89
$-2.41
$-3.01
Over the 6 years reported for Finch Therapeutics Group, Inc., borrowings decreased from $143.0M in 2019 to $28.0M in 2024, cash stood at $10.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 3.67 times.
Balance Sheet — 6 Years (USD millions)
Metric
2019
2020
2021
2022
2023
2024
Total Assets
$104.0M
$165.0M
$225.0M
$163.0M
$55.0M
$50.0M
Current Assets
$49.0M
$106.0M
$143.0M
$71.0M
$26.0M
$11.0M
Cash
$42.0M
$100.0M
$133.0M
$71.0M
$25.0M
$10.0M
Inventory
$0
$0
$-9.0M
$-4.0M
$0
$0
Receivables
$5.0M
$1.0M
$0
$0
$0
$0
Fixed Assets
$4.0M
$7.0M
$25.0M
$49.0M
$27.0M
$25.0M
Capital Work in Progress
$0
$0
$0
$0
$0
$0
Investments
$0
$0
$2.0M
$3.0M
$2.0M
$2.0M
Other Assets
$18.0M
$18.0M
$18.0M
$0
$0
$0
Total Liabilities
$163.0M
$261.0M
$23.0M
$67.0M
$32.0M
$41.0M
Current Liabilities
$7.0M
$11.0M
$15.0M
$15.0M
$4.0M
$3.0M
Borrowings
$143.0M
$2.0M
$6.0M
$52.0M
$30.0M
$28.0M
Other Liabilities
$20.0M
$259.0M
$17.0M
$15.0M
$2.0M
$13.0M
Equity
$0
$0
$0
$0
$0
$0
Reserves
$-60.0M
$-96.0M
$202.0M
$96.0M
$23.0M
$9.0M
For Finch Therapeutics Group, Inc., operating cash flow was positive in 0 of 6 reported years; free cash flow in the latest year was $0; free cash flow was positive in 0 of 6 years; financing activities used $1.0M in the latest year, which covers debt repayment, dividends and buybacks.
Cash Flow Statement — 6 Years (USD millions)
Metric
2019
2020
2021
2022
2023
2024
Operating Cash Flow
$-17.0M
$-31.0M
$-67.0M
$-75.0M
$-32.0M
—
Investing Cash Flow
$-2.0M
$-5.0M
$-32.0M
$-4.0M
$1.0M
—
Financing Cash Flow
$0
$0
$1.0M
$0
$-1.0M
—
Net Cash Flow
$35.0M
$58.0M
$36.0M
$-62.0M
$-46.0M
—
Free Cash Flow
$-18.0M
$-34.0M
$-83.0M
$-77.0M
$-32.0M
$0
Valuation & Return Ratios
Metric
Value
PEG Ratio
-0.01
EV / EBITDA
-2.47
FCF Yield
-192.35%
Quick Ratio
3.39
Interest Coverage
—
Return 1Y
-16.67%
Return 3Y
54.55%
Return 5Y
-97.57%
Finch Therapeutics Group, Inc. (FNCHQ) financials — frequently asked questions
What is Finch Therapeutics Group, Inc.'s annual revenue?
Finch Therapeutics Group, Inc. (FNCHQ) reported annual revenue of $0 in its most recent fiscal year.
What is Finch Therapeutics Group, Inc.'s net profit?
Finch Therapeutics Group, Inc. (FNCHQ) reported a net loss of $14.0M in its most recent fiscal year.
What is FNCHQ EV/EBITDA?
Finch Therapeutics Group, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -2.47. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.